Form D · Biotechnology
Aldebaran Therapeutics, Inc.
Waltham, MA · CIK 0001918979
Offering snapshot reported Mar 28, 2022 · SEC filing
- Reported sold
- $800K Offering amount: $1.2M
- Investors reported
- 20 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 9, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 28, 2022 | Initial | $800,000 | No comparison | 20 | SEC filing |
Offering details
- Securities
- Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-439130
Source: Form D, filed Mar 28, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Carlos Loya | Director, Executive |
| Lauren Mifflin | Director |
| Chris Pacheco | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
275 Second Ave Ste. 200
Waltham, MA, 02451
Waltham, MA, 02451